MICHELE BUSTARD: Open Payments
NPI 1720591902 · MULLICA HILL, NJ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$463 in 24 payments from 13 companies in 2025. Trend: 2023 $309 · 2024 $368 · 2025 $463
Food & beverage: $463
| Company | Payments | Amount |
|---|---|---|
| Bayer Healthcare Pharmaceuticals Inc. | 4 | $94 |
| Fresenius USA Marketing, Inc. | 4 | $88 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 3 | $49 |
| SCPHARMACEUTICALS INC. | 2 | $40 |
| Calliditas Therapeutics US Inc. | 2 | $32 |
| Vifor Pharma, Inc. | 2 | $30 |
| Daiichi Sankyo Inc. | 1 | $22 |
| Novartis Pharmaceuticals Corporation | 1 | $21 |
| Lilly USA, LLC | 1 | $21 |
| Apellis Pharmaceuticals, Inc. | 1 | $20 |
Products named: Kerendia, VELPHORO, JARDIANCE, FUROSCIX, TARPEYO, Veltassa, INJECTAFER, Fabhalta.
Industry payments across NJ — which companies pay providers there.
